Index A
ABCs. See Adenoid basal carcinomas See Adenoid Abdomen, ectopic pregnancy in, 1089 Ablation, 519 endometrial, for abnormal uterine bleeding, 490 submucosal leiomyomata/fibroid and, 519 Abnormal uterine bleeding, 47 471, 1, 486–490 in fourth decade, causes of, 490t 490 t in fifth decades, 471 causes of, 490t 490 t in sixth decade, 490t 490t causes of, 472 f clinical evaluation for, 486–488 definitions of, 472t 472t diagnostic considerations according to age for, 488–489 diagnostic evaluation of, 488 endometrial adenocarcinoma and, 589 endometrial polyp and, 490t 490t , 493 hysteroscopy for, 487–488 management of, 489–490 oral contraceptive therapy and, 488–489 from placenta previa, 1236 from placental abruption, 1228 submucosal leiomyoma/fibroid and, 504 in third and fourth decades, 471 Abortion. See Postabortion complications; See Postabortion Recurrent pregnancy loss; Spontaneous abortion Abruptio placentae. See Placental abruption See Placental Abruption-oligohydramnios sequence, chronic, 1223–1224 Abscess of anus, 231 fungal funisitis with superficial microabscesses, 1157 f ovarian, 790 f periclitoral, 85–86, 85 f Absent vagina, 16 Acantholytic dermatosis of vulvocrural area (ADV), 43–44, 44 f . See also Grover also Grover disease differential diagnosis of, 41t 41t Acantholytic dyskeratosis, 119 119 Acardiac twinning, 1240–1241, 1242 f Accelerated delivery, 1219–1225 1219–1225 ACCs. See Adenoid cystic carcinomas See Adenoid Achilles’ tendon, Reiter syndrome and, 30 Acid-fast bacilli (AFB), 498 Acne vulgaris, 70 Acquired immunodeficiency syndrome (AIDS) anus and, 233 fetal death caused by, 1199 SD and, 31 Acquired lymphangiectasia, 214–215, 214–215, 215 f Actinomyces Actinomyc es israelii, israelii, 503–504 Actinomycosis,, 503–504 Actinomycosis Active thrombosis, 119 1191–1 1–1193 193 Acute atherosis, 1154–1 1154–1155 155 Acute catastrophic demise, 1183–1 1183–1189 189 amniotic fluid embolism and, 1188 placental abruption and, 1184–1185, 1186 f ruptured vasa previa and, 1185–1187, 1187 f
Acute catastrophic demise (Continued) umbilical cord prolapse and, 1183–1184 uterine rupture and, 1188–1189 Acute inflammatory cells, 1161 1161 Acute villitis, 1167, 1167, 1169 1169 f Acyclovir,, 94 Acyclovir AD. See Atopic dermatitis See Atopic Adenocarcinoma. See also Glandular also Glandular neoplasia; specific diseases or disease sites in anal canal, 227 of anal mucosa, 249–250 of anus, 249–250 of Bartholin gland, 174 cervical neuroendocrine carcinoma and, 431 43 1 of cervix categories of, 400b 400b diagnosis and management of, 401–422 HPV and, 375–376 endometrioid intraepithelial neoplasia and, 534 endometriosis and, 286 f of fistula, 250 HP and, 107–109 HRT and, 806–807 infiltrative invasion of, 398 f intestinal endometriosis and, 807 f invasive endocervical, 399–40 399–401 1 metastatic, 438 f to cervix, 415–416, 416t 416t oral contraceptives and, 375–376 ovarian endometriosis and, 806–807 reactive endocervical cells and, 379–380, 380 f –381 –381 f smoking and, 376 of vagina, 285–286 of vulva, 165–172 Adenocarcinoma in situ (AIS), 375, 377 f –378 –378 f , 380 f adenosquamous carcinoma and, 388 cervical intraepithelial neoplasia and, 385 columnar differentiation and, 403, 403 f criteria for, 377 diagnosis and management of, 385–401 differential diagnosis of, 388–390 with early invasion, 398 f endocervical subtype of, 385–387 endometrioid carcinoma and, 402 endometrioid subtype of, 387 false-negative interpretations with, 379–380 histologic criteria for, 388t 388 t HPV and, 375–376 HSIL and, 383, 384 f intestinal subtype of, 387, 387 f menstrual or directly sampled endometrial cells and, 379, 380 f Pap smears for, 375 reactive endocervical cells and, 379–380, 380 f –381 –381 f stratified type of, 388 subtle variants of, 388 subtypes of, 385–388 superficial, 388 at transformation zone, 386 f tubal subtype of, 387–388 Adenocarcinomas arising in diverticula, 177
Adenofibroma, 870–874, 870 870 f –875 –875 f cervical, 447 endometrioid, 895 of fallopian tube, 744, 748 f Müllerian, 286 Adenoid basal carcinomas (ABCs), 406 f of cervix, 406–408 Adenoid cystic carcinomas (ACCs), 407 f of Bartholin gland, 172–174, 173 f –174 –174 f of cervix, 406–408 Adenolipoma, 209 Adenoma, of Bartholin gland, 11 111, 112 112 f Adenoma malignum, 408, 409 f endometrioid, 413 f glandular hyperplasia and, 408–4 408–412, 12, 408t 408 t Adenomatoid tumors, 699, 699 f of fallopian tube, 741–742, 744 f –745 –745 f of peritoneum, 831 Adenomatous polyposis coli (APC), 822 Adenomyoma, 445–447 atypical polypoid, 698, 698 f –699 –699 f clinical background of, 445 diagnostic criteria for, 445–447 differential diagnosis of, 446–447 gross exam for, 445 histologic features of, 445–446, 446 f immunohistochemistry of, 446 outcome and management for, 447 uterine smooth muscle tumors and, 697–699, 698 f Adenomyomatous polyp, endometrial polyp and, 493, 495 f Adenomyosis, 487 endometrial adenocarcinoma and, 623–631, 624 f uterine smooth muscle tumors and, 697–699, 697 f –698 –698 f Adenosarcoma, 699–702, 699–702, 700 f –701 –701 f , 924 carcinosarcomas and, 637 f cervical, 447–449 clinical background of, 447 differential diagnosis of, 449, 450 f –451 –451 f gross exam for, 447 histologic features of, 447–448, 448 f immunohistochemistry of, 448 outcome and management for, 449 clinical presentation of, 699–700 definition of, 699 differential diagnosis of, 701–702, 702 f endometrial polyp and, 496 f histopathologic features of, 700 molecular features of, 702 prognosis and management of, 702 rhabdomyosarcoma and, 701 f Adenosquamous carcinoma, 403 f of cervix, 402–403 clear cell, 403–404 glassy cell, 403–404, 404 f of vulva, 164–165, 165 f Adhesions fallopian tubes and, 731, 734 f of ovary, 762–763, 763 f Adipose tissue, 520, 520 f Adnexal gland benign tumors of, 102t 102t , 106–111 carcinomas of, 172 Paget disease with, 168 f
Note: Page numbers followed by “ f ” refer to illustrations; page numbers followed by “ t ” refer to tables; page numbers followed by “ b” refer to boxes. 1254